Cullinan Oncology Analyst Ratings
Cullinan Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/15/2023 | 339.37% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/03/2023 | 66.96% | Morgan Stanley | $27 → $19 | Maintains | Overweight |
| 11/21/2022 | 75.75% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/13/2022 | 119.68% | SVB Leerink | $36 → $25 | Maintains | Outperform |
| 03/18/2022 | 365.73% | HC Wainwright & Co. | $55 → $53 | Maintains | Buy |
| 06/07/2021 | 277.86% | Morgan Stanley | $40 → $43 | Maintains | Overweight |
| 06/04/2021 | 383.3% | HC Wainwright & Co. | $48 → $55 | Maintains | Buy |
| 06/04/2021 | 374.52% | SVB Leerink | $48 → $54 | Maintains | Outperform |
| 04/27/2021 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 04/19/2021 | 251.49% | Morgan Stanley | $38 → $40 | Maintains | Equal-Weight |
| 03/30/2021 | 321.79% | HC Wainwright & Co. | $47 → $48 | Maintains | Buy |
| 02/02/2021 | 383.3% | Evercore ISI Group | → $55 | Initiates Coverage On | → Outperform |
| 02/02/2021 | 356.94% | SVB Leerink | → $52 | Initiates Coverage On | → Outperform |
| 02/02/2021 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
| 02/01/2021 | 313.01% | HC Wainwright & Co. | → $47 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 02/15/2023 | 339.37% | HC Wainwright公司 | →$50 | 重申 | →購買 |
| 02/03/2023 | 66.96% | 摩根士丹利 | $27→$19 | 維護 | 超重 |
| 2022年11月21日 | 75.75% | BTIG | →$20 | 開始承保 | →購買 |
| 2022年05月13日 | 119.68% | SVB Leerink | $36→$25 | 維護 | 跑贏大盤 |
| 03/18/2022 | 365.73% | HC Wainwright公司 | $55→$53 | 維護 | 買 |
| 06/07/2021 | 277.86% | 摩根士丹利 | $40→$43 | 維護 | 超重 |
| 06/04/2021 | 383.3% | HC Wainwright公司 | $48→$55 | 維護 | 買 |
| 06/04/2021 | 374.52% | SVB Leerink | $48→$54 | 維護 | 跑贏大盤 |
| 04/27/2021 | - | 摩根士丹利 | 升級 | 等重→超重 | |
| 04/19/2021 | 251.49% | 摩根士丹利 | $38→$40 | 維護 | 等重 |
| 03/30/2021 | 321.79% | HC Wainwright公司 | $47→$48 | 維護 | 買 |
| 02/02/2021 | 383.3% | Evercore ISI集團 | →$55 | 開始承保 | →跑贏大盤 |
| 02/02/2021 | 356.94% | SVB Leerink | →$52 | 開始承保 | →跑贏大盤 |
| 02/02/2021 | - | 摩根士丹利 | 開始承保 | →等重 | |
| 02/01/2021 | 313.01% | HC Wainwright公司 | →$47 | 開始承保 | →購買 |
What is the target price for Cullinan Oncology (CGEM)?
庫利南腫瘤(CGEM)的目標價格是多少？
The latest price target for Cullinan Oncology (NASDAQ: CGEM) was reported by HC Wainwright & Co. on February 15, 2023. The analyst firm set a price target for $50.00 expecting CGEM to rise to within 12 months (a possible 339.37% upside). 5 analyst firms have reported ratings in the last year.
庫利南腫瘤公司(納斯達克代碼：CGEM)的最新目標價是由HC Wainwright&Co.於2023年2月15日報道的。這家分析公司將目標價定為50美元，預計CGEM將在12個月內上漲(可能上漲339.37%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Cullinan Oncology (CGEM)?
庫利南腫瘤學(CGEM)的最新分析師評級是多少？
The latest analyst rating for Cullinan Oncology (NASDAQ: CGEM) was provided by HC Wainwright & Co., and Cullinan Oncology reiterated their buy rating.
對庫利南腫瘤公司(納斯達克代碼：CGEM)的最新分析師評級是由HC Wainwright&Co.提供的，庫利南腫瘤公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Cullinan Oncology (CGEM)?
庫利南腫瘤學(CGEM)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cullinan Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cullinan Oncology was filed on February 15, 2023 so you should expect the next rating to be made available sometime around February 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與庫利南腫瘤公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。庫利南腫瘤學的上一次評級是在2023年2月15日提交的，所以你應該預計下一次評級將在2024年2月15日左右的某個時候提供。
Is the Analyst Rating Cullinan Oncology (CGEM) correct?
分析師對庫利南腫瘤學(CGEM)的評級正確嗎？
While ratings are subjective and will change, the latest Cullinan Oncology (CGEM) rating was a reiterated with a price target of $0.00 to $50.00. The current price Cullinan Oncology (CGEM) is trading at is $11.38, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的庫利南腫瘤學(CGEM)評級被重申，目標價在0.00美元至50.00美元之間。庫利南腫瘤公司(CGEM)目前的交易價格為11.38美元，在分析師的預測範圍內。